These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11920412)

  • 41. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis.
    Temple AR; Benson GD; Zinsenheim JR; Schweinle JE
    Clin Ther; 2006 Feb; 28(2):222-35. PubMed ID: 16678643
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment.
    Briot K; Gossec L; Kolta S; Dougados M; Roux C
    J Rheumatol; 2008 May; 35(5):855-61. PubMed ID: 18381782
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study.
    Clegg DO; Reda DJ; Abdellatif M
    Arthritis Rheum; 1999 Nov; 42(11):2325-9. PubMed ID: 10555027
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis.
    Bissonnette R; Papp K; Maari C; Yao Y; Robbie G; White WI; Le C; White B
    J Am Acad Dermatol; 2010 Mar; 62(3):427-36. PubMed ID: 20159310
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Infliximab in spondylarthropathy--influence on bone density.
    Demis E; Roux C; Breban M; Dougados M
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S185-6. PubMed ID: 12463474
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?
    Baeten D; Kruithof E; Van den Bosch F; Van den Bossche N; Herssens A; Mielants H; De Keyser F; Veys EM
    Ann Rheum Dis; 2003 Sep; 62(9):829-34. PubMed ID: 12922954
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First study of infliximab treatment in patients with chronic obstructive pulmonary disease.
    van der Vaart H; Koëter GH; Postma DS; Kauffman HF; ten Hacken NH
    Am J Respir Crit Care Med; 2005 Aug; 172(4):465-9. PubMed ID: 15937294
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.
    Brooklyn TN; Dunnill MG; Shetty A; Bowden JJ; Williams JD; Griffiths CE; Forbes A; Greenwood R; Probert CS
    Gut; 2006 Apr; 55(4):505-9. PubMed ID: 16188920
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up.
    Kruithof E; Van den Bosch F; Baeten D; Herssens A; De Keyser F; Mielants H; Veys EM
    Ann Rheum Dis; 2002 Mar; 61(3):207-12. PubMed ID: 11830424
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.
    Deodhar A; Gensler LS; Sieper J; Clark M; Calderon C; Wang Y; Zhou Y; Leu JH; Campbell K; Sweet K; Harrison DD; Hsia EC; van der Heijde D
    Arthritis Rheumatol; 2019 Feb; 71(2):258-270. PubMed ID: 30225992
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations.
    Generini S; Giacomelli R; Fedi R; Fulminis A; Pignone A; Frieri G; Del Rosso A; Viscido A; Galletti B; Fazzi M; Tonelli F; Matucci-Cerinic M
    Ann Rheum Dis; 2004 Dec; 63(12):1664-9. PubMed ID: 15297279
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Report of a preliminary discontinued double-blind, randomized, placebo-controlled trial of the anti-TNF-α chimeric monoclonal antibody infliximab in complex regional pain syndrome.
    Dirckx M; Groeneweg G; Wesseldijk F; Stronks DL; Huygen FJ
    Pain Pract; 2013 Nov; 13(8):633-40. PubMed ID: 23692303
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety, and biological immunomodulation.
    De Keyser F; Baeten D; Van den Bosch F; Kruithof E; Mielants H; Veys EM
    Rheum Dis Clin North Am; 2003 Aug; 29(3):463-79. PubMed ID: 12951862
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Disease controlling antirheumatic therapy in spondyloarthropathy.
    Dougados M
    J Rheumatol Suppl; 2001 Jun; 62():16-20. PubMed ID: 11409153
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
    Elliott MJ; Maini RN; Feldmann M; Kalden JR; Antoni C; Smolen JS; Leeb B; Breedveld FC; Macfarlane JD; Bijl H
    Lancet; 1994 Oct; 344(8930):1105-10. PubMed ID: 7934491
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment of inflammatory diseases: safety of long-term use of infliximab].
    Schaible TF
    Presse Med; 2001 Mar; 30(12):610-3. PubMed ID: 11317923
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial.
    Salvarani C; Macchioni P; Manzini C; Paolazzi G; Trotta A; Manganelli P; Cimmino M; Gerli R; Catanoso MG; Boiardi L; Cantini F; Klersy C; Hunder GG
    Ann Intern Med; 2007 May; 146(9):631-9. PubMed ID: 17470831
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Infliximab in primary Sjögren's syndrome: one-year followup.
    Steinfeld SD; Demols P; Appelboom T
    Arthritis Rheum; 2002 Dec; 46(12):3301-3. PubMed ID: 12483735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.